Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11247696 | 0.75 | TSHR (0.40) | TSHRMAPTALDH1A1GAA | |
| SCHEMBL5494369 | 0.74 | ARG1 (0.31) | — | |
| SCHEMBL13278810 | 0.72 | ALDH1A1 (0.36) | TSHRMAPTCACNA1BAPBA1ALDH1A1 | |
| SCHEMBL27814476 | 0.72 | ALDH1A1 (0.36) | TSHRMAPTCACNA1BAPBA1ALDH1A1 | |
| SCHEMBL1580236 | 0.71 | — | — | |
| SCHEMBL11198413 | 0.71 | — | — | |
| SCHEMBL20253786 | 0.69 | CYP3A4 (0.36) | TSHRMAPTCACNA1BAPBA1ALDH1A1 | |
| SCHEMBL7712121 | 0.68 | MAPT (0.34) | TSHRMAPTCACNA1BAPBA1ALDH1A1 | |
| SCHEMBL351761 | 0.68 | DPP4 (0.36) | TSHRALDH1A1GAAPOLBCYP3A4 | |
| SCHEMBL17361179 | 0.68 | ALDH1A1 (0.40) | TSHRMAPTALDH1A1GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248963-A1 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY | 2004-12-09 | — | — | US | disclosed |
| JP-2004307446-A | NEW IONIC LIQUID | TOKYO KASEI KOGYO KK | 2004-11-04 | — | — | JP | disclosed |
| EP-1463713-A1 | PRODRUGS OF EXCITATORY AMINO ACIDS | ELI LILLY AND COMPANY (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003045898-A1 | PRODRUGS OF EXCITATORY AMINO ACIDS | ELI LILLY AND COMPANY (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248963-A1 | Prodrugs of excitatory amino acids | SLC1A2, SLC1A1, SLC1A3 | TSHR 1034/4885MAPT 777/4885CACNA1B 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.